CVSCVS Health

Health care · Pharmacies · NYSE

Employees: 300,000
Headquarters: Woonsocket, RI
CEO: J. David Joyner
Next results: around Feb 9, 2027

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. Below: what the staff asked CVS, and the company's answer to each question, quoted from the letters. A question is not an accusation; most reviews end with the company adding detail to its next filing.

All reviews 5 Non-GAAP measures 2 Revenue 2 Segments 1 Results discussion (MD&A) 1 Liquidity and cash 1 Debt 1 Legal and contingencies 1

Form 10-K for the Fiscal Year Ended December 31, 2022

2023-05-11 to 2023-05-15 · 1 question · 1 letter from the SEC, 0 from the company

Review closed 2023-05-15

SegmentsResults discussion (MD&A)

SEC letter of 2023-05-11 ↗ no reply letter on EDGAR

Segment Analysis · Health Care Benefits Segment, page 79

SEC asked

Your disclosure in the last paragraph on page 80 indicates that "[b]ased on the Company's membership at December 31, 2022, 21% of the Company's Medicare Advantage members were in plans with 2023 star ratings of at least 4.0 stars, compared to 87% of the Company's Medicare Advantage members being in plans with 2022 star ratings of at least 4.0 stars based on the Company's membership at December 31, 2021." We also
Rest of the question

note that your 2023 star ratings will be used to determine which of your Medicare Advantage plans have four stars or higher and qualify for bonus payments in 2024. Please revise to quantify, if material, the impact that the significant decline in your plans with four stars or higher could have on your bonus payments in future periods.

CVS answered

No reply letter found.

In its next report

First report after the SEC's letter of 2023-05-11: 10-Q filed 2023-08-02 ↗, against the 10-Q filed 2023-05-03 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2023-05-15

4 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

2024-11-21 · CVS: letter to the SEC · CVS Health Corporation · Form 10-K for Fiscal Year Ended December 31, 2023 · File No. 001-01011
2023-05-15 · CVS: letter to the SEC · CVS Health Corporation · Form 10-K for Fiscal Year Ended December 31, 2022 · Filed...
2018-02-09 · CVS: asks the SEC to declare a registration effective · CVS Health Corporation · Registration Statement on Form S-4 · File No. 333-222412
2018-02-08 · CVS: asks the SEC to declare a registration effective · CVS Health Corporation · Registration Statement on Form S-4 · Filed January 4, 2018 ·...

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 21 letters filed since 2018-01-22. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Work on CVS in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/CVS/export.csv") into a cell.